Organ on chip Companies
Organ-on-a-chip technology involves creating microscale models of human organs on small chips for various applications, including drug testing, disease modeling, and personalized medicine.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Organ-on-a-chip Companies Update
Mar 2023: The adult stem cell (ASC)-derived tubular organoids have been released by MIMETAS, a pioneer in organ-on-a-chip-based disease models, in an assay-ready state. ASC-derived Colon and Kidney Organoid tubules are two organoid-based products MIMETAS offers as part of its OrganoReady® product range. Their early-access consumers will thus be the first globally to receive license-free access to donor-relevant, functional organoid tubules of reliable quality. SUB Since organoids are produced from ASCs directly, donor-specific characteristics are preserved without reprogramming or stem cell transformation. Using HUB organoid technology in conjunction with MIMETAS' microfluidic platform, OrganoPlate®, organoids are developed as perfused 3D tubular structures accessible from both the apical and basal sides.
June 2023: The first supplier of cutting-edge in vitro models, Emulate, Inc., announced the early access program launch of the Emulate Chip-A1TM Accessible Chip. The new Organ-Chip design allows users to create greater tissues inside the epithelial culture chamber and employ additional drug treatment options, such as topical or aerosolized applications. This design builds upon the original Chip-S1 model, which models tissue-vascular connections with relevant biomechanical forces like stretch and flow. By combining gels up to 3 mm thick inside the Chip-A1's accessible culture chamber, incorporating stroma into the epithelial layer, forming stratified epithelia, and applying organ-specific biomechanical pressures, researchers can recreate intricate 3D tissues.List of Organ-on-a-chip Key companies in the market
- CN Bio Innovations Limited (UK)
- Emulate, Inc. (US)
- TissUse GmbH (Germany)
- MIMETAS BV (Netherlands)
- Hµrel Corporation
- Nortis, Inc. (US)
- InSphero (Switzerland)
- TARA Biosystems, Inc. (US)
- Axosim (US)
- Organovo Holdings Inc. (US)
- BioIVT (US)
- HemoShear Therapeutics, LLC (US)
Organ on chip Market Highlights:
Organ on chip Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
